Previous studies evaluating the prognostic role of CD11b expression level in AML patients have enrolled participants with different ethnicity and different subtypes, adopted varied cut-off value for CD11b positivity ranging from 20% to 32% and conducted different treatment for recruited participants. This evidence concerns the gene ITGAM and acute myeloid leukemia.